Skip to main content
Premium Trial:

Request an Annual Quote

Isis Pharmaceuticals and Nitto Denko s Solid Support and Dharmacon s DharmaFect


Isis Pharmaceuticals and Nitto Denko said this week that that have developed a new solid support for the manufacture of oligonucleotides.

According to the companies, solid support is the base structure used in the synthesis of oligonucleotides such as siRNAs. The new product, they added, is cheaper to manufacture than currently used solid supports and has the potential to increase yield.

The product will be marketed by Kinovate Life Sciences, a subsidiary of Nitto Denko. Isis will receive royalties on sales.

Dharmacon has introduced DharmaFect, a line of siRNA transfection reagents.

According to the company, the line consists of four different products that are effective in different cell types.

DharmaFect 1 exhibits the highest efficiency of siRNA delivery with the least impact on cell viability across the broadest range of cell types, said the company. DharmaFect 2 exhibits the least toxicity of all the lipids, while DharmaFect 3 delivers siRNA efficiently in certain cell lines such as LNCaP. DharmaFect 4 works well for mouse and rat cell lines, Dharmacon added.

Additional details about the DharmaFect line can be found at

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.